Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 115 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2014', provides an overview of the Dry (Atrophic) Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dry (Atrophic) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dry (Atrophic) Macular Degeneration Overview 9
Therapeutics Development 10
Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview 10
Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis 11
Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies 12
Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 14
Dry (Atrophic) Macular Degeneration - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Dry (Atrophic) Macular Degeneration - Products under Development by Companies 19
Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes 21
Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development 22
Acucela Inc. 22
Alimera Sciences, Inc. 23
Bioheart, Inc. 24
Catalyst Biosciences, Inc. 25
Cell Cure Neurosciences, Ltd. 26
Eleven Biotherapeutics Inc. 27
EyeCyte, Inc. 28
Foamix Pharmaceuticals Ltd. 29
Genentech, Inc. 30
GlaxoSmithKline plc 31
Icon Bioscience, Inc. 32
Inotek Pharmaceuticals Corporation 33
MacuCLEAR, Inc. 34
Neurotech Pharmaceuticals, Inc. 35
Ocata Therapeutics, Inc. 36
Ophthotech Corp. 37
pSivida Corp. 38
Tacere Therapeutics, Inc. 39
Dry (Atrophic) Macular Degeneration - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
AdipoCell - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ARC-1905 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
EBI-028 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
emixustat hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
fluocinolone acetonide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Gene Therapy for Ocular Diseases - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GSK-933776 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
IBI-70090 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
lampalizumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MA09-hRPE - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MC-1101 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
minocycline Gel - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NM-9405 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NT-501 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OpRegen - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
OpRegen Plus - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RC-1 Alpha - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RST-001 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules for Age Related Macular Degeneration - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for AMD - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Stem Cell Therapy for Dry Atrophic Macular Degeneration - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Synthetic Peptides to Modulate CD36 Receptor for Ischemic Heart Disease and Macular Degeneration - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
TNX-234 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
TT-231 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Dry (Atrophic) Macular Degeneration - Recent Pipeline Updates 85
Dry (Atrophic) Macular Degeneration - Dormant Projects 105
Dry (Atrophic) Macular Degeneration - Discontinued Products 106
Dry (Atrophic) Macular Degeneration - Product Development Milestones 107
Featured News & Press Releases 107
Oct 16, 2014: Acucela's Emixustat Hydrochloride, In Development For Geographic Atrophy Associated with Dry Age-Related Macular Degeneration, Subject Of Podium Presentation At The American Academy Of Ophthalmology 2014 Annual Meeting 107
Dec 17, 2013: Bioheart Announces Clinical Study for Dry Macular Degeneration 107
Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 107
Oct 01, 2013: Roche to present data on Lampalizumab at investor event 108
Aug 27, 2013: Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 109
May 08, 2013: Acucela And Otsuka Pharma Announce Phase IIa Results Of Emixustat Hydrochloride In Patients With Geographic Atrophy Associated With AMD At ARVO 2013 Annual Meeting 110
Apr 24, 2013: Acucela Initiates Phase IIb/III Clinical Trial Of Emixustat Hydrochloride In Subjects With Geographic Atrophy Associated With Dry AMD 111
Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference 111
May 07, 2012: Acucela Presents New Data From Phase IIa Trial Of ACU-4429 In Patients With Dry AMD 112
Apr 24, 2012: Acucela To Present Clinical Data From Phase IIa Trial Of ACU-4429 At ARVO 2012 Annual Meeting 113
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115

List of Tables
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2014 10
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Dry (Atrophic) Macular Degeneration - Pipeline by Acucela Inc., H2 2014 22
Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2014 23
Dry (Atrophic) Macular Degeneration - Pipeline by Bioheart, Inc., H2 2014 24
Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2014 25
Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2014 26
Dry (Atrophic) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2014 27
Dry (Atrophic) Macular Degeneration - Pipeline by EyeCyte, Inc., H2 2014 28
Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2014 29
Dry (Atrophic) Macular Degeneration - Pipeline by Genentech, Inc., H2 2014 30
Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline plc, H2 2014 31
Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2014 32
Dry (Atrophic) Macular Degeneration - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 33
Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR, Inc., H2 2014 34
Dry (Atrophic) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2014 35
Dry (Atrophic) Macular Degeneration - Pipeline by Ocata Therapeutics, Inc., H2 2014 36
Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2014 37
Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2014 38
Dry (Atrophic) Macular Degeneration - Pipeline by Tacere Therapeutics, Inc., H2 2014 39
Assessment by Monotherapy Products, H2 2014 40
Number of Products by Stage and Target, H2 2014 42
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 46
Number of Products by Stage and Molecule Type, H2 2014 48
Dry (Atrophic) Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2014 85
Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2014 105
Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2014 106